Key facts
- This page summarizes Flagship Pioneering Fund VII General Partner LLC's Form 3 filing for Seres Therapeutics, Inc. (MCRB).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jul 2022, 17:00.
Flagship Pioneering Fund VII General Partner LLC - 05 Jul 2022 Form 3 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- MCRB
- Reported as of
- 05 Jul 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 07 Jul 2022, 17:00:37 UTC
- Prior SEC filing
- 01 Jun 2022
- Next SEC filing
- 27 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- Flagship Pioneering Fund VII General Partner LLC, By: Flagship Pioneering, Inc., its manager, By: /s/ Noubar B. Afeyan, PhD., Name: Noubar B. Afeyan, Ph.D., Title: Chief Executive Officer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Flagship Pioneering Fund VII General Partner LLC filed Form 3 for Seres Therapeutics, Inc. (MCRB) on 07 Jul 2022.
Change
- Previous filing in this sequence was filed on 01 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MCRB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,825,495
- Date
- 05 Jul 2022
- Ownership
- By Flagship Pioneering Fund VII, L.P.
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On July 5, 2022, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 5,825,495 shares of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share.
Footnote F2
Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.